BiomX : Introduction

Company Introduction

Safe Harbor Statement

This presentation contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current beliefs, expectations and assumptions. When we discuss our ability to quickly generate clinical proof of concept in patients and the advantages of our BOLT platform, our leadership position in phage technology and timing of, among other things, clinical trials initiations, conclusion and receipt of results and meeting milestones relating to our development plan as well as commercialization plans, we are making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward- looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review additional disclosures we make in our filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov. Except as required by law, we are under no duty to (and expressly disclaim any such obligation to) update or revise any of the forward- looking statements, whether as a result of new information, future events or otherwise.

2

What we do

We develop disease modifying therapies based on natural or engineered phage cocktails as precision medicines to target and specifically destroy harmful bacteria

Our R&D platform enables generation of clinical proof of concept in patients within 12-18 months from project initiation*

• In certain indications the length of clinical validation may be longer depending on indication, identity of target bacteria, recruitment rate, cohort size and other factors.

3

Unique position as leader in phage technology

Only clinical stage phage company focusing on chronic indications

Technology

• BOLT phage therapy platform - Rapid path from discovery to clinic
• Scalable in-housemanufacturing - can support annually over 50 different phage at a clinical grade

Partnerships

• Acne collaboration with leading global cosmetic company
• Biomarker discovery collaborations in IBD
• • Janssen (J&J)
  • Boehringer Ingelheim

Pipeline

• Positive Phase 1 data for topical delivery of BX001 in subjects with acne prone skin
• Positive Phase 1a data of pharmacokinetic study for IBD/PSC1 evaluating oral delivery
• 4 Phase 2 readouts expected by mid 20222

Financing and investors

• Publicly traded (NYSE:PHGE)
• Equity raised: $140M

• Secured debt of up to $30M

• Cash runway at least mid 2023

1. Inflammatory Bowel Disease (IBD) , Primary Sclerosing Cholangitis (PSC).
2. Phase 2 results in acne, Phase 1b/2a results in cystic fibrosis, Phase 2 results in atopic dermatitis, Phase 1b/2a results in IBD/PSC

4

Phage: Nature's precision tool to target bacteria

Each phage binds only to	Phage have an amplifying lifecycle
specific bacterial strains

1. Locate
2. Inject

3 Infect

4 Multiply

5 Assemble

6 Eradicate

7 Seek

Source: Kortright et al. (2019), Cell Host & Microbe

5